Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update [Yahoo! Finance]
Indivior PLC - Ordinary Shares (INDV)
Company Research
Source: Yahoo! Finance
GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2025, and provided a corporate update. “We have seen great progress in the first six months of 2025, both in terms of d
Show less
Read more
Impact Snapshot
Event Time:
INDV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INDV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INDV alerts
High impacting Indivior PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
INDV
News
- Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- A Fresh Look at Indivior (INDV) Valuation Following Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Indivior Concludes Legacy U.S. Department of Justice Matter [Yahoo! Finance]Yahoo! Finance
- Indivior Concludes Legacy U.S. Department of Justice MatterPR Newswire
INDV
Earnings
- 10/30/25 - Beat
INDV
Sec Filings
- 11/20/25 - Form 8-K
- 11/14/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- INDV's page on the SEC website